InvestorsHub Logo
Followers 2
Posts 927
Boards Moderated 0
Alias Born 09/27/2005

Re: Gold Seeker post# 16474

Friday, 10/03/2008 10:57:49 AM

Friday, October 03, 2008 10:57:49 AM

Post# of 30387
It is extremely significant. It adds credibility to the viability of Recaf.
NO MARKER TO DATE has achieved everything Recaf has accomplished.
Bash all you want you can't stop the honor nor the invitation to present at the ISOBM.
You can't stop the research from further validating recaf occurring in outside institutions.
You can't stop the publication of data.
You can't stop commercialization of the Elisa test.
You can't take away our million dollar investment from Inverness.
You can't take away our rapid testwhich detects cancer from a single drop of blood.
You can't take away the fact that recaf works on automized diagnostic analzers.
You can't take away the fact the Dr Moro has and will continue to accomplish every task put before him. He truly grasps the knowledge required to cure cancer. He said he has preliminary results that are confirming this and I would say that it will likely happen.

You owe many investors an apology. Backpeddle away!

Also as a footnote I asked:
This is significant enough to get the attention of television news. Goshen is launching a wide pilot study. Why not notify the news media?

Reply (within 10 minutes) by management:
Thank you for your question.

The news media has already been notified by way of this morning's press release. Those press releases are issued to every radio and TV station in Canada and the US as well as every daily newspaper and scientific journal. A medical journal has also contacted AGORACOM requesting visual images for an article it intends to put together. We will post published articles in magazines to this IR hub and label them as Industry Reports.

AGORACOM


Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.